Arcus Biosciences, Inc. (RCUS)

USD 15.17

(-5.66%)

Long Term Debt Summary of Arcus Biosciences, Inc.

  • Arcus Biosciences, Inc.'s latest annual long term debt in 2023 was 110 Million USD , down -5.98% from previous year.
  • Arcus Biosciences, Inc.'s latest quarterly long term debt in 2024 Q1 was 128 Million USD , down 0.0% from previous quarter.
  • Arcus Biosciences, Inc. reported annual long term debt of 117 Million USD in 2022, up 0.1% from previous year.
  • Arcus Biosciences, Inc. reported annual long term debt of 116.88 Million USD in 2021, up 666.82% from previous year.
  • Arcus Biosciences, Inc. reported quarterly long term debt of 20 Million USD for 2024 Q2, down 0.0% from previous quarter.
  • Arcus Biosciences, Inc. reported quarterly long term debt of 115 Million USD for 2023 Q3, down -0.86% from previous quarter.

Annual Long Term Debt Chart of Arcus Biosciences, Inc. (2023 - 2016)

Historical Annual Long Term Debt of Arcus Biosciences, Inc. (2023 - 2016)

Year Long Term Debt Long Term Debt Growth
2023 110 Million USD -5.98%
2022 117 Million USD 0.1%
2021 116.88 Million USD 666.82%
2020 15.24 Million USD 0.0%
2019 - USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%

Peer Long Term Debt Comparison of Arcus Biosciences, Inc.

Name Long Term Debt Long Term Debt Difference
ADC Therapeutics SA 112.73 Million USD 2.422%
Alto Neuroscience, Inc. 151.33 Million USD 27.315%
Annovis Bio, Inc. - USD -Infinity%
Biohaven Pharmaceutical Holding Company Ltd. 27.56 Million USD -298.999%
Ginkgo Bioworks Holdings, Inc. 221.83 Million USD 50.414%
Nuvation Bio Inc. 2.03 Million USD -5305.405%
Nuvation Bio Inc. 2.03 Million USD -5305.405%
Theriva Biologics, Inc. 162 Thousand USD -67801.235%
Zymeworks Inc. 22.46 Million USD -389.738%